ABCB5 and diabetic foot: In a clinical trial (NCT03267784), one or two topical applications of ABCB5+ MSCs at a dose of 2 × 106 cells/cm2 to therapy-refractory diabetic foot ulcers lead to a median wound surface area reduction of 59% (full analysis set, n  =  23), 64% (per-protocol set, n  =  20) and 67% (subgroup of responders, n  =  17) by week 12.